Literature DB >> 25503805

A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.

Jason H Karnes, Robert M Cronin, Jerome Rollin, Alexander Teumer, Claire Pouplard, Christian M Shaffer, Carmelo Blanquicett, Erica A Bowton, James D Cowan, Jonathan D Mosley, Sara L Van Driest, Peter E Weeke, Quinn S Wells, Tamam Bakchoul, Joshua C Denny, Andreas Greinacher, Yves Gruel, Dan M Roden1.   

Abstract

Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect of heparin treatment resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. No genome-wide evaluations have been performed to identify potential genetic influences on HIT. Here, we performed a genome-wide association study (GWAS) and candidate gene study using HIT cases and controls identified using electronic medical records (EMRs) coupled to a DNA biobank and attempted to replicate GWAS associations in an independent cohort. We subsequently investigated influences of GWAS-associated single nucleotide polymorphisms (SNPs) on PF4/heparin antibodies in non-heparin treated individuals. In a recessive model, we observed significant SNP associations (odds ratio [OR] 18.52; 95% confidence interval [CI] 6.33-54.23; p=3.18×10(-9)) with HIT near the T-Cell Death-Associated Gene 8 (TDAG8). These SNPs are in linkage disequilibrium with a missense TDAG8 SNP. TDAG8 SNPs trended toward an association with HIT in replication analysis (OR 5.71; 0.47-69.22; p=0.17), and the missense SNP was associated with PF4/heparin antibody levels and positive PF4/heparin antibodies in non-heparin treated patients (OR 3.09; 1.14-8.13; p=0.02). In the candidate gene study, SNPs at HLA-DRA were nominally associated with HIT (OR 0.25; 0.15-0.44; p=2.06×10(-6)). Further study of TDAG8 and HLA-DRA SNPs is warranted to assess their influence on the risk of developing HIT.

Entities:  

Keywords:  Pharamacogenetics; heparins; thrombocytopenia

Mesh:

Substances:

Year:  2014        PMID: 25503805      PMCID: PMC4433536          DOI: 10.1160/TH14-08-0670

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  46 in total

1.  Anti-heparin-platelet factor 4 antibodies after cardiopulmonary bypass: role of HLA expression.

Authors:  D Paparella; M Micelli; B Favoino; M D'Alò; T Fiore; L de Luca Tupputi Schinosa
Journal:  Haematologica       Date:  2001-03       Impact factor: 9.941

2.  Inference of population structure using multilocus genotype data.

Authors:  J K Pritchard; M Stephens; P Donnelly
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

3.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

Review 4.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Temporal aspects of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

6.  Cohort profile: the study of health in Pomerania.

Authors:  Henry Völzke; Dietrich Alte; Carsten Oliver Schmidt; Dörte Radke; Roberto Lorbeer; Nele Friedrich; Nicole Aumann; Katharina Lau; Michael Piontek; Gabriele Born; Christoph Havemann; Till Ittermann; Sabine Schipf; Robin Haring; Sebastian E Baumeister; Henri Wallaschofski; Matthias Nauck; Stephanie Frick; Andreas Arnold; Michael Jünger; Julia Mayerle; Matthias Kraft; Markus M Lerch; Marcus Dörr; Thorsten Reffelmann; Klaus Empen; Stephan B Felix; Anne Obst; Beate Koch; Sven Gläser; Ralf Ewert; Ingo Fietze; Thomas Penzel; Martina Dören; Wolfgang Rathmann; Johannes Haerting; Mario Hannemann; Jürgen Röpcke; Ulf Schminke; Clemens Jürgens; Frank Tost; Rainer Rettig; Jan A Kors; Saskia Ungerer; Katrin Hegenscheid; Jens-Peter Kühn; Julia Kühn; Norbert Hosten; Ralf Puls; Jörg Henke; Oliver Gloger; Alexander Teumer; Georg Homuth; Uwe Völker; Christian Schwahn; Birte Holtfreter; Ines Polzer; Thomas Kohlmann; Hans J Grabe; Dieter Rosskopf; Heyo K Kroemer; Thomas Kocher; Reiner Biffar; Ulrich John; Wolfgang Hoffmann
Journal:  Int J Epidemiol       Date:  2010-02-18       Impact factor: 7.196

7.  Evaluation of a method to identify and categorize section headers in clinical documents.

Authors:  Joshua C Denny; Anderson Spickard; Kevin B Johnson; Neeraja B Peterson; Josh F Peterson; Randolph A Miller
Journal:  J Am Med Inform Assoc       Date:  2009-08-28       Impact factor: 4.497

8.  Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition.

Authors:  Henry Watson; Simon Davidson; David Keeling
Journal:  Br J Haematol       Date:  2012-10-09       Impact factor: 6.998

9.  The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages.

Authors:  B Scheuerer; M Ernst; I Dürrbaum-Landmann; J Fleischer; E Grage-Griebenow; E Brandt; H D Flad; F Petersen
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

10.  Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia.

Authors:  Claire Pouplard; Pascale Cornillet-Lefebvre; Redha Attaoua; Dorothée Leroux; Carinne Lecocq-Lafon; Jérôme Rollin; Florin Grigorescu; Philippe Nguyen; Yves Gruel
Journal:  Thromb Res       Date:  2012-01-10       Impact factor: 3.944

View more
  27 in total

1.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

2.  Pharmacological inhibition of GPR4 remediates intestinal inflammation in a mouse colitis model.

Authors:  Edward J Sanderlin; Mona Marie; Juraj Velcicky; Pius Loetscher; Li V Yang
Journal:  Eur J Pharmacol       Date:  2019-03-28       Impact factor: 4.432

Review 3.  Cardiovascular pharmacogenomics: current status and future directions.

Authors:  Dan M Roden
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

4.  What's new about heparin-induced thrombocytopenia type II.

Authors:  Yasser Sakr
Journal:  Intensive Care Med       Date:  2015-04-23       Impact factor: 17.440

Review 5.  Phenome-Wide Association Studies as a Tool to Advance Precision Medicine.

Authors:  Joshua C Denny; Lisa Bastarache; Dan M Roden
Journal:  Annu Rev Genomics Hum Genet       Date:  2016-05-04       Impact factor: 8.929

Review 6.  Personalized medicine: Genetic risk prediction of drug response.

Authors:  Ge Zhang; Daniel W Nebert
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

Review 7.  Pathogenesis of thrombosis: cellular and pharmacogenetic contributions.

Authors:  Dileep D Monie; Emma P DeLoughery
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

8.  Association between the HLA-DRB1*03:01-DQB1*02:01 haplotype and PF4/heparin antibodies.

Authors:  Ray Zhang; Brian F Duffy; Vinzenz Lange; Charles S Eby; Chang Liu
Journal:  Blood Adv       Date:  2019-10-22

9.  Integrating electronic health record genotype and phenotype datasets to transform patient care.

Authors:  D M Roden; J C Denny
Journal:  Clin Pharmacol Ther       Date:  2016-01-26       Impact factor: 6.875

10.  Targeted resequencing of a locus for heparin-induced thrombocytopenia on chromosome 5 identified in a genome-wide association study.

Authors:  Anika Witten; Juliane Bolbrinker; Andrei Barysenka; Matthias Huber; Frank Rühle; Ulrike Nowak-Göttl; Edeltraut Garbe; Reinhold Kreutz; Monika Stoll
Journal:  J Mol Med (Berl)       Date:  2018-06-22       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.